Author Index

A

Abderhalden RT, 353
Abele R, 505
Abeloff MD, 639
Abuchowski A, 1077
Adhemar J-P, 665
Ahlgren JD, 223
Ahmann DL, 169, 537
Ahmed F, 431
Aisner J, 73, 133, 323, 831, 979
Al-Sarraf M, 447, 897
Alberts DS, 1, 532, 1001
Anderson J, 1015
Antunez AR, 219
Ardalan B, 491
Arlin ZA, 919
Armand J-P, 329
Armata J, 164
Armitage JO, 413, 601
Arora RK, 531
Arseneau JC, 355
Ashenhurst J, 869

B

Baba N, 1093
Babcock GF, 673
Baca CD, 291, 727
Bachur NR, 73
Bains M, 781
Baker LH, 115, 358, 655, 897
Baker MA, 947
Balcerzak SP, 1093
Barlock AL, 755
Barlow JJ, 149
Bartosek I, 555
Baum ES, 815
Baumgardner R, 639
Bedikian AY, 747, 841, 877
Beex L, 179
Begg CB, 689, 711
Beggiolin G, 350
Belt RJ, 439, 883
Benckhuysen C, 567
Benjamin RS, 341, 427
Bennetts RW, 747
Benraad T, 179
Bernardo G, 135
Bernheim J, 505
Berry DH, 173
Bianchi C, 171, 731
Bickers J, 427, 693
Billings AA, 869
Biraghi M, 171
Biran H, 924
Biran S, 924
Birch R, 530, 901, 1027
Bird G, 13
Bisel HF, 537
Bitran JD, 531, 869
Blackstein ME, 947
Blair M, 469
Blatt J, 145
Bloomfield CD, 685
Blum RH, 331
Blumenreich MS, 525
Blumenschein GR, 33, 383, 465, 775
Bodey GP, 165, 197, 341, 465, 521, 699, 747, 775, 877
Boesen EM, 241
Bolis G, 172
Bonnet J, 447
Bono VH, Jr, 57
Botnick LE, 797
Bottomley R, 443, 447
Boyd MR, 755
Bozzino JM, 351
Bradner WT, 291, 727
Bramwell VHC, 509
Braverman I, 920
Brenner DE, 231
Briscoe K, 823
Britell JC, 335, 337, 909
Brodovsky H, 65
Brøgger A, 607
Broggini M, 669
Broun GO, Jr, 237
Broun GO, 1027
Brown B, 615
Brown TC, 947
Bruno S, 53, 57
Budman DR, 535, 823
Bukowski RM, 219, 763
Bull JM, 1103
Bunn PA, Jr, 187, 905
Burgess AM, 873
Burgess MA, 313, 841
Burke PJ, 1007
Burnett W, 735
Burns CP, 601
Buttrick P, 531
Buyse M, 505

Buzdar AU, 775
Byar DP, 920
Byfield JE, 69

C

Cadman E, 507, 920
Calvo DB, III, 165
Calzavara MP, 171, 731
Camacho FJ, 170, 705
Cambareri RJ, 317
Campbell M, 897
Canellos GP, 17
Canti R, 1125
Carboni E, 135
Carey RW, 793, 823
Casanova L, 213
Casazza AM, 267
Cass D, 563
Cassani L, 731
Cassidy F, 987
Castle MC, 1043
Cerna I, 107
Chan PYM, 697
Chandler WF, 401, 803
Chang P, 73, 231
Chapman R, 525, 781
Chard R, 1015
Chawla MS, 973
Cheek W, 681
Chello PL, 1049
Chen M, 507
Chen T, 681
Chilcote R, 1015
Chin HW, 45
Citrin DL, 539, 651, 1083
Clarkson BD, 153, 207
Clink H McD, 259
Cobleigh MA, 659
Cohen AI, 651, 1083
Cohen MH, 187, 431, 529, 905, 965
Coirin AK, 1063
Coleman M, 823
Coles DT, 715, 1099
Colombo T, 669
Comis R, 477, 647
Cooper KR, 419
Cooper MR, 1043
Corder MP, 413
Cordes RC, 755
Corkery J, 887
Cornbleet MA, 241
Cornell CJ, Jr, 734
Corringham RET, 241
Costanzi J, 732
Cox JD, 811
Creagan ET, 169, 356, 453, 517, 537, 538, 715, 827, 1031
Creaven PJ, 431
Creech RH, 431, 895, 959
Crom W, 1021
Crooke ST, 291, 485, 727
Cummings G, 358, 655
Cumps E, 505
Currie ET, 973
Currie V, 127
Curtis JE, 947

D

Dahl GV, 995
Dail DH, 39, 165
Dakhil SR, 393, 401, 803
Davis FF, 1077
Davis HL, 459, 835
Davis JM, 793
Davis S, 955, 1077, 1113
Davis TE, 651, 711
De Jager RL, 329
DeBoer G, 947
DeVita VT, Jr, 1103
Decker DG, 1127
Degnan T, 535
Dellaquila C, 919
Denefrio JM, 163
Dent DM, 987
Desser RK, 869
Di Marco A, 267
DiStefano A, 33, 775
Dick FR, 413, 601
Dicke KA, 39, 377
Didolkar MS, 925
Diekamp U, 973
Diggs CH, 929
D'Incalci M, 172, 350, 669
Dixon D, 447, 601, 732
Doan K, 803
Doblin J, 153
Domae N, 79
Dombernowsky P, 123, 245
Donavan M, 431
Donelli MG, 669
Dorr RT, 1001
Dorschel NT, 639
Douglass H, 65
Dragon LH, 1007
Droz J-P, 665
Duncan GF, 495
Dutcher JS, 755

E

Eagan RT, 356, 453, 517, 715, 1031, 1099
Eakin DL, 352
Earhart RH, 459, 835
Edmonson JH, 536, 537, 538, 1127
Egan EM, 853
Egorin MJ, 73

Einhorn LH, 659
Eisenberger MA, 163
El Dareer SM, 101, 495
Elson MK, 485
Engstrom P, 65
Ensminger WD, 393, 401, 803
Ervin TJ, 331, 787
Ettinger DS, 639
Evans WE, 1021
Evans WK, 947
Eyre H, 427, 447

F

Fabian CJ, 253, 732
Fabian R, 787
Falkson G, 65, 529
Fandrich S, 477
Feld R, 947
Fer MF, 941
Ferraro JA, 345
Finkelstein T, 477
Fisher B, 363
Fisher R, 601
Fitzpatrick A, 477, 647
Fleming TR, 356
Floyd RA, 69
Foelsch E, 431
Ford LC, 1055
Fossieck BE, Jr, 187
Foster R, 363
Fraile RJ, 358, 655
Frankmann C, 197
Freeberg BL, 539
Freedman A, 629
Frei E, III, 331
Freireich EJ, 197, 521, 873, 877
Fried J, 153
Frytak S, 356, 453, 517, 536, 715, 1099
Fu KK, 697
Fuks JZ, 133
Furnival CM, 735

G

Gad-El-Mawla N, 357
Gagliano R, 447
Gahbauer R, 219
Garattini S, 555, 669
Garay G, 1109
Garnick MB, 17
Gaynon P, 815
Gelber RD, 65
Gescher A, 669
Gilchrist GS, 538
Giles GR, 13
Gill DP, 352
Gillespie M, 197
Ginsberg S, 477, 647
Ginther NC, 69
Gittes RF, 17
Glass A, 363
Glaubiger D, 145, 545
Glode LM, 327
Golbey R, 781
Goldstein MA, 797
Goodwin W, 359
Gough IR, 735
Gouyette A, 665
Grage TB, 685
Gralla RJ, 129, 513, 515, 705
Grant C, 615
Grdina D, 845
Greco FA, 349, 530, 941
Green AA, 1021
Green SB, 920
Green SJ, 169, 536, 537
Greenberg HS, 401, 803
Greenberg L, 815
Greenstreet R, 763
Griffiths JC, 69
Groppe CW, Jr, 219, 359, 763
Grossie VB, Jr, 1087
Guiliani FC, 267, 1063
Gupta RK, 1037
Gustafson J, 929
Gutterman JU, 383
Gynning I, 119

H

Haas CD, 115, 439, 883
Hagenbeek A, 575
Hahn D, 73
Hahn RG, 335, 711
Haidak DJ, 317
Hains FC, 469
Hall J, 13
Hall R, 13
Hall T, 689
Hamel E, 545
Hammond D, 815, 1015
Han T, 925
Hande KR, 349
Hane KR, 941
Hansen HH, 123, 245, 329, 703, 979
Hansen M, 703
Harberg J, 1083
Harder L, 35
Harrap KR, 259
Harris JR, 797
Harrison T, 987
Hartmann DW, 327
Hatfield AK, 353
Hattori S, 707

Haut A, 601
Havsteen H, 123
Hayata Y, 707
Hayes A, 1021
Hellman S, 797
Hemstreet GP, III, 29
Hersh EM, 383
Herzog AG, 797
Hester JP, 377
Hewlett JS, 219, 427
Higgins GR, 923
Hild J, 509
Hill DL, 101, 495
Hirao F, 707
Hoeschele JD, 1055
Hogan TF, 539
Holcenberg J, 249
Holiat SM, 1113
Holland JF, 677
Hong WK, 419
Hoogstraten B, 439, 443, 883
Hoppe RT, 935
Hornbeck CL, 69
Hortobagyi GN, 383, 775
Horton J, 65, 345, 689
Hoth DH, 317, 734, 1109
Houghton AN, 170, 703
Howard J, 525
Howarth CB, 1021
Howser DM, 249, 731
Hubbard SM, 755
Huberman MS, 905
Hubert DD, 1113
Hull EW, 693
Huth JF, 1037

I

Ibrahim E, 725
Ihde DC, 187, 755, [illegible]5
Ingle JN, 169, 356, [illegible]3, 517, 537, 715, 1099
Ionta MT, 135
Issell BF, 197

J

Jackson DV, 1043
Jacobs P, 987
Jacobs SJ, 891
Jayaram HN, 491
Jeffers WB, 841
Johnson G, 545
Johnson RK, 331
Johnsson J-E, 119
Johnston-Early A, 187, 529
Jones RB, 755
Jones SE, 611
Jordan WM, 187, 197
Joseph U, 439

K

Kahn AR, 501
Kaplan NO, 1063
Kaplan RS, 163
Karakousis CP, 925
Karlin DA, 747
Karp JE, 1007
Katz M, 137
Kawlinsky D, 995
Kean C, 1055
Keating MJ, 313, 377, 521
Kelsen DP, 781
Kemeny N, 127
Kenis Y, 505
Kennedy BJ, 685
Kenser TW, 491
Kerwin DM, 223
Khouri N, 639
Killen JY, 1129
Kim T, 173
Kimball AW, 1007
Kimball JC, 1121
Kindt GW, 401, 803
King HS, 987
Kirshner J, 477, 563
Kishimoto S, 707
Kleinknecht D, 665
Klepp O, 607
Klimo P, 715, 725
Kloppenborg P, 179
Klubes P, 107
Knight E, 21
Knost JA, 349, 941
Koeller J, 651
Koeller JM, 459, 835
Koenders A, 179
Kohn J, 259
Kohn L, 647
Komaki R, 811
Konishi T, 79
Koons LS, 965
Koriech OM, 351
Kostraba N, 685
Kovach JS, 1031
Koyama H, 728
Koziner B, 207
Kozloff MF, 869
Krementz ET, 321
Krivit W, 815, 1015
Kubota TT, 57
Kufe DW, 93, 331, 853
Kukla LJ, 973
Kuperminc M, 355
Kutas GJ, 947
Kvols LK, 356, 453, 517, 536, 715, 909, 1099

L

Lacave AJ, 329
Lacave J, 509
Lad TE, 973
Lagasse LD, 1055
Land VJ, 725
Larson CS, 973
Laster WR, 1117
Lawrence R, 137
Lawson RK, 891
Lawton JO, 13
LeRoy A, 73
Lee BJ, III, 207
Lees DE, 1103
Legha SS, 165, 341
Lehane D, 447
Lele S, 149
Lemoine R, 665
Lerner HJ, 363, 431, 965
Lessner HE, 163
Levene MB, 797
Levenson RM, Jr, 905
Levin Y, 277
Lewis BJ, 249
Libretti A, 171, 555, 731
Lichtiger B, 1121
Liesmann J, 253, 883
Lippi MG, 135
Litam JP, 39, 377
Livingston RB, 143
Lokich J, 887
Loo TL, 1087
Look AT, 995
Ludlum D, 345
Lui V, 121, 1105
Lynch G, 127

M

MacAdam A, 13
MacIntyre JM, 21
Macdonald JS, 53, 57, 317
Macquet J-P, 665
Maddison FE, 891
Magill GB, 513, 515
Magorien RD, 1093
Makuch R, 187
Malkasian GD, 1127
Man N-K, 665
Mangalik A, 327
Mangioni C, 172, 350
Marcial J, 213
Margolese R, 363
Markus S, 73
Marsh KC, 253
Marsoni S, 171, 731
Martelo OJ, 237
Martens ACM, 575
Maruyama Y, 45
Masaoka T, 707
Mascia V, 135
Masiel A, 532
Maskens AP, 329
Mason BA, 431
Mason C, 995
Massidda B, 135
Masud ARZ, 1123
Matheson T, 13
Matsuyama E, 79
Mattsson W, 119
Maurer LH, 767
Mayer RJ, 17
McCracken JD, 359
McCreanney J, 509
McCredie KB, 377, 427, 521
McElwain TJ, 241
McGhee KG, 259
McGuire WP, III, 973
McIlveen BM, 629
McKelvey EM, 165, 699
Mehta CR, 431, 959, 965
Mellette SJ, 355
Mellits ED, 639
Meshad MW, 331, 787
Metz R, 509
Meyskens FL, Jr, 1, 532
Millband L, 947
Miller D, 389, 787
Miller M, 563
Minna JD, 187, 905
Mira J, 143
Mitchell EP, 1129
Moertel CG, 65, 335, 909, 1031
Molin J, 583
Montgomery JA, 1117
Moore T, 681
Morasca L, 171, 731
Morgan GW, 629
Morgan LR, 693
Morgan SK, 173, 725
Mortimer J, 763
Morton DL, 1037
Mouridsen HT, 509
Muggiano A, 135
Murphy WK, 341, 699
Murray IPC, 629
Muss HB, 1043
Myers RE, 947

N

Natale RB, 129, 525
Needleman SW, 601
Nelson RB, 973
Neville AM, 259
Nguyen BV, 1121

Nichols WC, 356, 453, 517, 715, 827, 1099
Niederhuber J, 393, 401
Niitani H, 707
Nishioka K, 673
Nitschke R, 725, 1105
Nix W, 173
Noker PE, 495
Nomura T, 283
Noyes RD, 673

O

O'Bryan RM, 143
O'Connell MJ, 536, 909
O'Donnell JF, 823
O'Donnell M, 345
O'Fallon JR, 827
Ogden S, 615
Ogura T, 707
Oken MM, 485
Oldham RK, 349, 941
Omura GA, 530, 901, 1027
Opipari M, 897
Orbert B, 119
Order SE, 639
Orlandini O, 213
Ortega JA, 923
Osoba D, 947
Osterlind K, 245
Ostrow SS, 73, 323, 929
Otero J, 213
Ottema B, 947
Overgaard J, 501, 583
Owellen RJ, 469
Ozols RF, 731

P

Pagano M, 895
Paine RM, 259
Pajak TF, 734, 767
Panasci L, 477, 647
Panattiere F, 443
Panduro J, 703
Papps J, 1027
Park YK, 955
Pasco T, 213
Passe S, 207
Patterson RB, 1121
Patton TF, 253
Pavesi L, 135
Pavlovsky S, 1109
Pellegrini A, 135
Penta J, 53
Perez AG, 153
Perry MC, 823
Peterson BA, 685
Petrilli ES, 1055
Petruska PJ, 237
Phillips TL, 697
Piazza E, 171, 555, 731
Pieters G, 179
Pisoni MB, 731
Piver MS, 149
Pizzo PA, 145
Plager C, 341
Plager JE, 283
Plotkin D, 363
Posey LE, 693
Posner M, 787
Poster DS, 53, 57
Powis G, 1031
Prasad V, 351
Pratt CB, 1021
Prentice HG, 241
Pretorius RG, 1055
Pritchard KI, 947
Pugh R, 447
Pullen J, 1105
Purvis JD, 169, 335
Pyesmany A, 1015

Q

Quiroz L, 213
Quirt IC, 947

R

Rainey J, 693
Rambotti P, 955
Ransom JL, 1021
Redmond C, 363
Reich S, 477
Reimer RR, 219, 763
Restelli G, 171
Rhamy RK, 349
Ribi I, 383
Rice MR, 1063
Richards F, II, 1043
Richards F, III, 823
Richardson RL, 941
Richie JP, 17
Richman SP, 383, 873
Riela AR, 1121
Rios A, 383
Rivera G, 995
Robin E, 869
Robinson WA, 327
Robustelli della Cuna G, 135
Rørth M, 123
Rose JD, 1117
Rose WC, 299
Rosenberg SA, 739

Rosowsky A, 93, 853
Rubert M, 647
Rubin J, 335, 536, 909, 1031
Ruckdeschel JC, 345, 959, 965
Russo R, 555
Ryan D, 693

S

Saiki J, 447
Salas F, 213
Salazar OM, 959, 965
Salmon SE, 1, 532
Salner AL, 797
Samal B, 443
Samson MK, 358, 655
Samuels ML, 615
Sanani S, 1123
Santi AM, 555
Sargent L, 853
Sarma PR, 973
Savaraj N, 841
Savi G, 267
Savlov ED, 21
Sawada H, 79
Sawamura K, 707
Scaglione C, 1109
Scalzo T, 647
Scanni A, 171, 731
Scapaticci R, 171, 731
Scarpazza G, 171, 731
Schabel FM, Jr, 591
Schein PS, 223, 317, 1109, 1129
Schell F, 465
Schlein A, 291, 727
Schuette WH, 1103
Schulman P, 535
Schulz EJ, 529
Schurig JE, 727
Schutt AJ, 335, 909
Schwartz PE, 137
Seeger JF, 803
Seipp CA, 739
Sela B-A, 277
Selig DE, 615
Senzer N, 995, 1021
Sessa C, 172, 350
Sethi VS, 1043
Sexauer C, 173, 681
Shafer RB, 485
Shamberger RC, 739
Shapiro C, 869
Sharp TR, 69
Sherins RJ, 739
Shechtman L, 477
Shetty MR, 531
Shibata H, 363
Shurig JE, 291
Siegel SE, 923
Sigdestad CP, 845
Sigurdsson K, 119
Sikic BI, 223
Silverberg LJ, 697
Simon R, 323
Sindelar W, 911
Sirotnak FM, 1049
Skarin AT, 17
Skeel RT, 431
Slayton RE, 895
Smals A, 179
Smith FP, 223, 317, 1129
Smith R, 1103
Smith WE, 1113
Soehnlen B, 1, 532
Sogaard PE, 583
Solidoro A, 213
Sordillo PP, 513, 515
Sørensen PG, 245
Sörensen S, 123
Spaulding MB, 1123
Spitzer G, 39, 377
Sponzo RW, 431, 959
Spurr CL, 1043
Starling K, 681, 1105
Steele G, 93
Stephens R, 359
Sternson LA, 253
Stewart DJ, 313
Stolbach LL, 689
Strada MR, 135
Straus DJ, 207
Strike TA, 920
Stroehlein JR, 747
Strong JE, 485
Stuart JJ, 1043
Stuckey WJ, 881
Sulkes A, 924
Sutherland CM, 321
Sutherland JC, 929
Sylvester R, 509

T

Talley RL, 1093
Talley RW, 655
Temple C, Jr, 1117
Tepper J, 911
Ter Hart HGJ, 567
Terasawa T, 728
Thigpen T, 115, 443, 881
Thrall J, 393
Thynne GSJ, 735
Tichler T, 973
Tillery KF, 101
Todd RF, III, 17
Tomirotti M, 171, 731
Torain B, 157

Tormey DC, 677
Trader MW, 591
Triebel F, 327
Trigg ME, 145
Troner MB, 29
Tropé C, 119
Trueworthy R, 121

U

Uchino H, 79
Ueno WM, 317
Ungerleider RS, 719
Unverferth BP, 1093
Unverferth DV, 1093

V

Vago G, 731
Valdivieso M, 197, 747, 841, 873, 877
Valente I, 172
Vallejos C, 213
Van Dijk PJ, 567
Van Echo D, 323
Van Echo DA, 133, 831
van Eys J, 121, 681
Van Tosh A, 469
Vats TS, 121
Vaughn C, 881
Vaughn CB, 44[illegible]
Vaughn WP, 10[illegible]
Vélez-García E, 901
Vellekoop L, 39, 377
Vendrik C, 509
Verma DS, 39, 377
Vial R, 693
Vinciguerra V, 535
Vistica DT, 157
Vogi S, 965
Vogler WR, 389
Von Hoff DD, 133, 157, 249
Vosika GJ, 823

W

Wada T, 728
Waksvik H, 607
Walker MD, 920
Watson RC, 525
Webb MJ, 1127
Weichselbaum R, 787
Weick JK, 219, 611
Weinberg VE, 677
Weiner JH, 223
Weiss GB, 352
Weiss RB, 249, 677
Weissman C, 345
Welt S, 919
Weston BJ, 259
Whang-Peng J, 1103
Wheeler GP, 591
Wheeler R, 393, 401
Whitacre MY, 323, 831
White DR, 1043
Whitman G, 920
Whitson W, 811
Wick MM, 861
Wieand HS, 363
Wienblatt ME, 923
Wiernik PH, 73, 133, 231, 323, 831, 929
Williams SD, 659
Willis LL, 1129
Wilson H, 427, 732
Winton EF, 389
Witman G, 507, 920
Wittes RE, 129, 170, 705
Wolff J-PM, 329
Wolmark N, 363
Wolter J, 21, 355, 363
Woolley PV, 317, 1109, 1129
Wright JE, 93

Y

Yagoda A, 525
Yamada K, 707
Yamamura Y, 707
Yap B-S, 341, 521
Yap H-Y, 33, 465, 775
Yasumoto K, 707
Youness E, 313
Young AB, 45
Young CW, 170, 207
Young L, 1, 532
Young RC, 249, 731, 755

Z

Zamkoff K, 563
Zander AR, 39, 377, 699
Zawilla P, 973
Zeffren J, 525
Zervas MT, 793
Ziegler JL, 357

Subject Index

A

Acivicin
radiometric enzyme-inhibition technique for measuring in plasma, 491
Adverse effects, animals
bleomycin and talisomycin, pulmonary toxicity studies of, 291
bleomycin, pulmonary toxicity studies of, tested before and after its expiration date, 727
cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q_{10}, 79
2′-deoxycoformycin and 2′-deoxyadenosine, toxic and immunosuppressive activity of binary combinations of, 259
pulmonary toxicity studies of bleomycin and talisomycin, 291
reversal of methotrexate toxicity in mice by a calcium salt of citrovorum factor and related compounds, 1117
Adverse effects, man
AMSA, allergic reaction following the administration of, 919
bleomycin, prospective study of the pulmonary toxicity of continuously infused, 419
cardiac arrhythmia associated with AMSA in a child: a Southwest Oncology Group study, 1121
changes in hair pigmentation associated with cancer chemotherapy, 529
chronic urticarial reactions caused by doxorubicin-containing regimens, 353
cisplatin-induced anemia, 1121
cutaneous necrosis from chemotherapy in a patient with an arteriovenous fistula, 352
early pulmonary toxicity after high-dose administration of BCNU, 39
5-FU cardiotoxicity, 1123
hepatic toxicity of DTIC, 321
high-dose mechlorethamine, unanticipated side effects from treatment with, in patients with malignant melanoma, 327
human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration, 1093
methotrexate, anaphylactic reaction to high-dose, as adjuvant treatment of osteogenic sarcoma, 725
misuse of scalp hypothermia, 507
mitomycin C-induced skin ulceration remote from infusion site, 529
pulmonary disease as a complication of chlorozotocin chemotherapy, 223
radionuclide ejection fraction in doxorubicin toxicity, 629
reversible brachial plexopathy following primary radiation therapy for breast cancer, 797
venous thrombosis during multimodal treatment of primary breast carcinoma, 677
whole-body hypothermia for the treatment of cancer, physiologic response and toxicity in patients undergoing, 323
zinostatin-related pulmonary toxicity, 165
Allergic reactions *see* Adverse effects, man
AMSA
allergic reaction following the administration of, 919
cardiac arrhythmia associated with, in a child: a Southwest Oncology Group study, 1121
in adult sarcomas, phase II evaluation, 341
in lung cancer, phase II study, 655
in patients with small cell lung carcinoma, phase II trial, 133
treatment of advanced colorectal carcinoma with, 345
Anaphylaxis *see* Adverse effects, man
Anemia *see* Adverse effects, man
Anguidine
in patients with sarcomas unresponsive to prior chemotherapy, phase II trial of: a Southwest Oncology Group study, 881
Aniline mustard
enhanced cytostatic effectiveness of, against 7,12-dimethylbenz[α]anthracene-induced rat mammary tumors during regression in response to ovariectomy, 567
L-Asparaginase
comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and: a phase III trial, 1015
Azacitidine
intensive chemotherapy with daunorubicin, 6-thioguanine, cytarabine and, for the blastic transformation of chronic granulocytic leukemia, 389
pyrazofurin and, phase I study of, in refractory adult acute leukemia, 237
responses to aziridinylbenzoquinone, cisplatin, PCNU and: chemotherapeutic trials with hamster mesothelioma 10-24, 1113
VP-16-213 plus, effect remission induction of refractory childhood acute nonlymphocytic leukemia by, 995
Aziridinylbenzoquinone
responses to azacitidine, cisplatin, PCNU and: chemotherapeutic trials with hamster mesothelioma 10-24, 1113

B

Baker's antifol
in children with therapy-resistant solid tumors: a Southwest Oncology Group study, 725
BCG cell wall skeleton
toxic and therapeutic effects of administration into malignant effusions, 383
BCNU
combination with high-dose cyclophosphamide and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia, 377
early pulmonary toxicity after high-dose administration of, 39
intra-arterial chemotherapy with, for the treatment of malignant gliomas of the central nervous system: a preliminary report, 803
methyl-CCNU and, survival response of malignant gliomas to radiotherapy with or without, at the University of Kentucky Medical Center, 45
pharmacokinetics, differential pulse polarographic determination of, in patients with lung cancer, 555
treatment of recurrent lymphomas with vincristine, doxorubicin, prednisone and, (VBAP): a Southwest Oncology Group study, 611
Beta-adrenergic compounds
pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for, 1001
Bladder cancer *see* Cancer, bladder
Bleomycin
CCNU, vincristine and, re-evaluation of the combination in the treatment of malignant disseminated melanoma, 505
cisplatin, methotrexate and, (PBM) in treatment of advanced squamous cell carcinoma of the head and neck, 787
cisplatin, vindesine and, (DVB) combination chemotherapy for esophageal carcinoma, 781
combination with vinblastine in metastatic renal cell carcinoma, 349
combined with radiotherapy for advanced head and neck cancers: results of a phase I pilot study, 697
experimental studies on the radiation-modifying effect of, in malignant and normal mouse tissue in vivo, 583
four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group pilot study, 143
pharmacokinetics of, after im administration in man, 485
prospective study of the pulmonary toxicity of continuously infused, 419
pulmonary toxicity studies of talisomycin and, 291
pulmonary toxicity studies of, tested before and after its expiration date, 727
Bowel cancer *see* Cancer, bowel
Brain cancer *see* Cancer, brain
Breast cancer *see* Cancer, breast
Bronchogenic cancer *see* Cancer, bronchogenic
Bruceantin
administered on a weekly schedule, phase I study on, 883

C

CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
for epidermoid and large cell anaplastic carcinoma of the lung, 317
immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: a randomized trial, 973
versus HAM (hexamethylmelamine, doxorubicin, and methotrexate), chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, 959
Cancer *see* also leukemia
adenocarcinoma
ovarian, cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for, 149
ovarian, hexamethylmelamine in mustard-resistant, 530
bladder
transitional cell carcinoma, doxorubicin hypogastric infusion combined with hyperthermia therapy for, 891
transition cell carcinoma, oral VP-16-213 in: a phase II study, 703
urothelial malignancy, cyclophosphamide, doxorubicin, and cisplatin in the treatment of: a pilot study of the Southeastern Cancer Study Group, 29
bowel, large
carcinoma, advanced, phase II study of PALA in, 335
brain
malignant gliomas, survival response to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center, 45
primary germ cell tumor, systematic chemotherapy for: a pharmacokinetic study, 447
breast
acute toxicity during adjuvant chemotherapy for: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents, 363
advanced, VP-16-213 in patients with, phase II evaluation of: a Southwest Oncology Group study, 443
advanced, effect of tamoxifen in premenopausal Japanese women with, 728
advanced, ethinyl estradiol and medroxyprogesterone treatment in: a pilot study, 135
carcinoma, primary, venous thrombosis during multimodal treatment of, 677
carcinoma, tamoxifen-induced thrombosis during multimodal treatment of, 677
metastatic refractory, methyl-GAG in patients with, phase II evaluation, 465
metastatic, doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with, previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 33
metastatic, vindesine in patients with, phase II study, 659

recurrent, influence of estrogen receptor status on response to combination chemotherapy for, 763
refractory, vindesine in the treatment of: improvement in therapeutic index with continuous 5-day infusion, 775
reversible brachial plexopathy following primary radiation therapy for, 797
bronchogenic
carcinoma, ifosfamide: a weekly dose fractionated schedule in, 693
inoperable small cell carcinoma, chemotherapy for: EST 2575, generation II, 965
metastatic non-small cell carcinoma, chemotherapy for: EST 2575, generation III, HAM versus CAMP, 959
non-small cell carcinoma, cyclophosphamide, doxorubicin, and cisplatin in the treatment of, 947
small cell, vindesine in the treatment of, 245
central nervous system
implanted system for intraventricular drug infusion in, 401
cervical
advanced squamous cell, doxorubicin, vincristine, and 5-FU versus cyclophosphamide in, phase II randomized study of, 901
colon
adenocarcinoma, metastatic, of the colon and rectum, phase II study of cyclophosphamide and cytarabine in the treatment of, 163
advanced carcinoma, melphalan, vincristine, and 5-FU in: results of a pilot study, 869
colorectal
advanced adenocarcinoma, cyclophosphamide and cytarabine in the treatment of, phase II study of, 163
advanced carcinoma, indicine N-oxide (INDI) in patients with, phase II trial, 337
advanced carcinoma, iv 6-thioguanine in, phase II trial, 909
advanced carcinoma, treatment with AMSA, 345
carcinoma, metoprine in patients with, phase II evaluation, 127
chemotherapy for, with a combination of PALA and 5-FU, 747
ependymoma
adjuvant chemotherapy for medulloblastoma and, using iv vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study, 681
esophageal
carcinoma, cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for, 781
Ewing's sarcoma
high-dose melphalan and autologous bone marrow transplantation, treatment with, 242
glioma
intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report, 803
head and neck
advanced squamous cell carcinoma, treatment with cisplatin, bleomycin, and methotrexate (PBM), 787
advanced, PALA in patients with, phase II evaluation, 827
advanced, combined radiotherapy and bleomycin for: results of a phase I pilot study, 697
Hodgkin's disease
advanced, laparotomy in the re-evaluation of patients with, 685
combination chemotherapy salvage of heavily pretreated patients with: an analysis of prognostic factors in two chemotherapy trials and the literature, 207
refractory, other lymphomas, and chronic lymphocytic leukemia, phase II study of hexamethylmelamine in, 1027
lung
advanced large cell, evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in, 715
advanced non-small cell, cyclophosphamide, doxorubicin, and cisplatin in the treatment of, 941
advanced non-small cell, evaluation of an intermittent schedule of mitolactol in, 1099
AMSA in, phase II study, 655
differential pulse polarographic determination of BCNU pharmacokinetics in patients with, 555
epidermoid and large cell anaplastic carcinoma, CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for, 317
non-small cell carcinoma, results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable, 431
non-small cell carcinomas, combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive, 955
non-small cell, commentary: current status of chemotherapy for, 979
small cell anaplastic carcinoma, 5-FU in the treatment of: a phase II trial, 123
small cell and squamous cell, cyclophosphamide and VP-16-213 with or without cisplatin in, 453
small cell carcinoma, AMSA in patients with refractory, phase II trial, 133
small cell carcinoma, intensive induction chemotherapy in 54 patients with, 639
small cell carcinoma, prognostic factors in: a Cancer and Leukemia Group B study, 767
small cell carcinoma, vindesine in patients with, phase II trial, 129
small cell, laboratory parameters as an alternative to performance status in prognostic stratification of patients with, 187
small cell, risk of brain metastasis from, related to length of survival and prophylactic irradiation, 811
squamous cell and small cell, cyclophosphamide and VP-16-213 with or without cisplatin in, 453
unresectable non-small cell, immediate versus postponed combination chemotherapy (CAMP) for: a randomized trial, 973
lymphoma
adrenal response to serial cosyntropin stimulation after repeated high-dose prednisone administration in patients with, 563

chlorozotocin in leukemia and other hematologic malignancies, phase II study of, 1109
cutaneous T-cell, cisplatin treatment of, 920
diffuse histiocytic, after histologic conversion: a poor prognostic variant, 413
diffuse lymphocytic of the large cell (histiocytic) variety, treatment of stage III and IV: an interim report, 987
hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia, phase II study of, 1027
nodular poorly differentiated lymphocytic: changes in histology and survival, 929
non-Hodgkin's, histologic variation in: commentary, 935
recurrent, treatment with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group study, 611
malignant glioma
proper analysis of clinical trials for, 920
medulloblastoma
adjuvant chemotherapy for ependymoma and, using iv vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study, 681
melanoma
malignant disseminated, re-evaluation of the combination of CCNU, vincristine, and bleomycin in the treatment of, 505
malignant, and soft tissue sarcomas, phase II study of diglycoaldehyde in, 823
malignant, chlorozotocin in patients with, phase II evaluation, 705
malignant, tamoxifen in the treatment of, 531
malignant, unanticipated side effects from treatment with high-dose mechlorethamine in patients with, 327
ovarian cancer and, update on in vitro testing of new drugs in, 532
neuroblastoma
doxorubicin and cisplatin therapy in children with, resistant to conventional therapy: a Southwest Oncology Group study, 1105
working conference on treatment trials, 719
osteogenic sarcoma
anaphylactic reaction to methotrexate used in high doses as an adjuvant treatment of, 725
osteosarcoma
effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of, 739
ovarian
advanced, combination chemotherapy for: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide, 137
advanced, progestin therapy for: a phase II Eastern Cooperative Oncology Group trial, 895
advanced, spirogermanium in, phase II study, 119
carcinoma, uptake of melphalan by human cells and its relationship to the amino acid content of ascitic fluid, 157
melanoma and, update on in vitro testing of new drugs in, 532
pancreatic
single-agent and combination chemotherapy of, 65
renal cell
advanced, vinblastine-CCNU, triazinate, and dactinomycin in, phase II study, 711
metastatic carcinoma, combination of vinblastine and bleomycin in, 349
metastatic carcinoma, study of tamoxifen and the influence of certain prognostic factors in: a Southwest Oncology Group study, 447
renal
carcinoma, treatment with oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine, phase III randomized trial, 689
metastatic adenocarcinoma, trial of methyl-GAG in the treatment of patients with, 17
sarcoma
adult, AMSA in, phase II evaluation, 341
advanced, chlorozotocin in patients with, phase II evaluation, 513
advanced, doxorubicin and dactinomycin therapy for, 231
advanced, vindesine sulfate in patients with, phase II evaluation, 515
assessment of in vivo effectiveness of tumoricidal chemotherapy and radiation therapy by serial analysis of tumor-associated urinary antigen titers in patients with, 1037
doxorubicin compared with cycloleucine in the treatment of, 21
unresponsive to prior chemotherapy, anguidine in patients with, phase II trial: a Southwest Oncology Group study, 881
soft tissue
advanced sarcoma, treatment with chlorozotocin: a phase II trial of the EORTC Soft Tissue and Bone Sarcoma Group, 509
solid tumors
advanced, simultaneous treatment with cisplatin and radiation therapy for: a pilot study, 219
pharmacokinetic evaluation of cisplatin in children with malignant: a phase II study, 1021
therapy-resistant, Baker's antifol in children with: a Southwest Oncology Group study, 725
tolerance to single-dose dactinomycin in combination chemotherapy for, 145
squamous cell
advanced, combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with, phase II study, 517
testicular
stage III, iv hyperalimentation and chemotherapy for, 615
thymoma
invasive, treated with cisplatin, 531
urothelial
cyclophosphamide, doxorubicin, and cisplatin in

treatment of: a pilot study of the Southeastern Cancer Study Group, 29
transitional cell carcinoma, cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of, phase II trial, 897
CAP (cyclophosphamide, doxorubicin, and cisplatin)
combination chemotherapy for extensive non-small cell carcinomas of the lung, 955
in the treatment of urothelial transitional cell carcinoma, phase II trial, 897
Cardiac arrhythmia *see* Adverse effects, man
Cardiomyopathy *see* Adverse effects, animals
Cardiotoxicity *see* Adverse effects, man
CCNU
methyl-CCNU or BCNU chemotherapy, survival response of malignant gliomas to radiotherapy with or without, at the University of Kentucky Medical Center, 45
vincristine, bleomycin and, re-evaluation of the combination in the treatment of malignant disseminated melanoma, 505
Cell culture studies
cytarabine and daunorubicin, kinetic and cytotoxic effects of, 153
new drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay, 1
Cervical cancer *see* Cancer, cervical
CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin)
as second-line chemotherapy for adenocarcinoma, 149
Chlorozotocin
attempted amelioration of myelotoxicity from, by glucose administration, phase I trial, 647
in leukemia and other hematologic malignancies, phase II study, 1109
in patients with advanced sarcomas, phase II evaluation, 513
in patients with malignant melanoma, phase II evaluation, 705
pulmonary disease as a complication of chemotherapy with, 223
treatment of advanced soft tissue sarcomas with: a phase II trial of the EORTC Soft Tissue and Bone Sarcoma Group, 509
Cisplatin
anemia induced by, 1121
avoidance of renal toxicity by 24-hour infusion of, 351
bleomycin, methotrexate and, in treatment of advanced squamous cell carcinoma of the head and neck, 787
combined with cyclophosphamide and doxorubicin in the treatment of urothelial transitional cell carcinoma, 897
combined with cyclophosphamide, hexamethylmelamine, and doxorubicin as second-line chemotherapy for ovarian adenocarcinoma, 149
combined with dianhydrogalactitol and doxorubicin, phase II study in patients with advanced squamous cell lung cancer, 517
combined with vindesine and bleomycin, chemotherapy for esophageal carcinoma, 781
comparison of the iv and ip routes of administration of, in dogs, 1055
cyclophosphamide, doxorubicin and, (CAP) combination chemotherapy for extensive non-small cell carcinomas of the lung, 955
cyclophosphamide, doxorubicin and, in the treatment of advanced non-small cell lung cancer, 941
cyclophosphamide, doxorubicin and, in the treatment of non-small cell bronchogenic carcinoma, 947
doxorubicin and, therapy in children with neuroblastoma resistant to conventional therapy: a Southwest Oncology Group study, 1105
nephrotoxicity, measurement of urinary beta-microglobulin in the detection of, 1083
pharmacokinetic evaluation of, in children with malignant solid tumors: a phase II study, 1021
radiation therapy and, simultaneous treatment for advanced solid tumors: a pilot study, 219
responses to azacitidine, aziridinylbenzoquinone, PCNU, and cisplatin: chemotherapeutic trials with hamster mesothelioma 10-24, 1113
selective enhancement of radiation response in a C3H mammary carcinoma by, 501
treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide and, and intensive iv hyperalimentation, 197
treatment of cutaneous T-cell lymphoma, 920
Citrovorum factor
reversal of methotrexate toxicity in mice by a calcium salt of, and related compounds, 1117
Clinical cancer
laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer, 187
proper analysis of clinical trials for malignant glioma, 920
update on in vitro testing of new drugs in ovarian cancer and melanoma, 532
Colon cancer *see* Cancer, colon
Colorectal cancer *see* Cancer, colorectal
Cosyntropin
adrenal response to serial stimulation with, after repeated high-dose prednisone administration in patients with lymphoma, 563
Cutaneous necrosis *see* Adverse effects, man
Cycloleucine
comparison with doxorubicin in the treatment of sarcomas, 21
Cyclophosphamide
chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP, 959
cisplatin, doxorubicin and, (CAP) in the treatment of urothelial transitional cell carcinoma, phase II trial, 897
cytarabine and, in the treatment of metastatic adenocarcinoma of the colon and rectum, phase II study, 163
doxorubicin, cisplatin and, (CAP) combination chemotherapy for extensive non-small cell carcinomas of the lung, 955

doxorubicin, cisplatin and, in the treatment of advanced non-small cell lung cancer, 941
doxorubicin, cisplatin and, in the treatment of non-small cell bronchogenic carcinoma, 947
doxorubicin, cisplatin and, in treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group, 29
doxorubicin, methotrexate, procarbazine and, (CAMP) for epidermoid and large cell anaplastic carcinoma of the lung, 317
evaluation of VP-16-213, doxorubicin, cisplatin and, (V-CAP) in advanced large cell lung cancer, 715
four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group pilot study, 143
hexamethylmelamine and, compared with doxorubicin and cyclophosphamide in combination chemotherapy for advanced ovarian cancer: a prospective randomized trial, 137
hexamethylmelamine, doxorubicin, cisplatin and, as second-line chemotherapy for ovarian adenocarcinoma, 149
high-dose, combination with BCNU and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia, 377
intermittent continuous iv infusion of high-dose, for remission induction in acute lymphocytic leukemia, 213
therapeutic synergism with methotrexate in murine L1210 leukemia, biochemical and pharmacologic study of, 107
treatment of advanced adenocarcinoma of the lung with doxorubicin, cisplatin and, 197
versus doxorubicin, vincristine, and 5-FU in advanced squamous cell carcinoma of the cervix, phase II randomized study, 901
VP-16-213 and, with or without cisplatin in squamous cell and small cell lung cancers, 453

Cytarabine
cyclophosphamide and, in the treatment of metastatic adenocarcinoma of the colon and rectum, phase II study, 163
daunorubicin and, kinetic and cytotoxic effects of on cells in culture, 153
intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine and, for the blastic transformation of chronic granulocytic leukemia, 389

Cytostatic agents
chromosome analyses of nurses handling, 607

D

Dactinomycin
doxorubicin and, therapy for advanced sarcomas, 231
single-dose, tolerance to in combination chemotherapy for solid tumors, 145
vinblastine-CCNU, triazinate and, in advanced renal cell cancer, 711

DAP (dianhydrogalactitol, doxorubicin, and cisplatin)
combination in patients with advanced squamous cell lung cancer, phase II study, 517

DATA (daunorubicin, azacitidine, 6-thioguanine, and cytarabine)
intensive chemotherapy with, for the blastic transformation of chronic granulocytic leukemia, 389

Daunorubicin
basic amino acid and dipeptide derivatives of, improved antitumor activity on EL4 leukemia cells in mice, 277
combined with ICRF-159 or doxorubicin, studies in mice treated with, 267
cytarabine and, kinetic and cytotoxic effects of, on cells in culture, 153
intensive chemotherapy with azacitidine, 6-thioguanine, cytarabine and, for the blastic transformation of chronic granulocytic leukemia, 389

3-Deazauridine
in adults with acute leukemia, phase I-II study of, 521

Demecolcine (Colcemid)
action of, in the murine Sarcoma 180 tumor, 283

2′-Deoxyadenosine
toxicity and immunosuppressive activity of binary combinations of 2′-deoxycoformycin and, 259

2′-Deoxycoformycin
toxicity and immunosuppressive activity of binary combinations of 2′-deoxyadenosine and, 259

Deoxycytidine
rescue of thymidine cytotoxicity in L1210 ascites by elevated endogenous levels of, 853

Dianhydrogalactitol
combination with doxorubicin and cisplatin, phase II study in patients with advanced squamous cell lung cancer, 517
for remission induction in children with acute leukemia, phase II clinical trial: a Southwest Oncology Group study, 121
in lung cancer, phase II evaluation: a Southwest Oncology Group study, 115

Dibromodulcitol *see* Mitolactol

Dichloromethylene diphosphonate
iv, in cancer-associated hypercalcemia: a phase I–II evaluation, 651

Diglycoaldehyde
in malignant melanomas and soft tissue sarcomas, phase II study, 823

Dihydroxyanthracenedione
administered on a 5-day iv schedule, phase I clinical study, 841
phase I trial of, 831

Dihydroxybenzylamines
trihydroxybenzylamines and, as novel quinol antitumor agents in experimental leukemia in vivo, 861

DON (6-diazo-5-oxo-norleucine)
phase I and pharmacokinetic studies of, 1031

Dopamine
and levodopa analogs: dihydroxy and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo, 861

Doxorubicin
CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung, 317

chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP, 959
chronic urticarial reactions caused by doxorubicin-containing regimens, 353
cisplatin, doxorubicin, and cyclophosphamide (CAP), phase II trial with, in the treatment of urothelial transitional cell carcinoma, 897
combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide, 137
combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung, 955
combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP), phase II study of, in patients with advanced squamous cell lung cancer, 517
cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer, 941
cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma, 947
cyclophosphamide, doxorubicin, and cisplatin in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group, 29
cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma, 149
doxorubicin and cisplatin therapy in children with neuroblastoma resistant to conventional therapy: a Southwest Oncology Group study, 1105
doxorubicin and dactinomycin therapy for advanced sarcomas, 231
doxorubicin hypogastric artery infusion combined with hyperthermia therapy for transitional cell carcinoma of the bladder, 891
doxorubicin in the treatment of sarcomas, comparison with cycloleucine, 21
doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 33
doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix, phase II randomized study of, 901
evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer, 715
four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group pilot study, 143
human myocardial morphologic and functional changes in the first 24 hours after administration, 1093
ICRF-159 combined with daunorubicin or doxorubicin, studies in mice treated with, 267
pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds, 1001
radionuclide ejection fraction in doxorubicin cardiotoxicity, 629
treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation, 197
treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group study, 611

4′-Doxorubicin
effect of analogs on heterotransplantation of human tumors in congenitally athymic mice, 1063

Drug delivery
implanted system for intraventricular drug infusion in central nervous system tumors, 401
totally implanted system for hepatic arterial chemotherapy, 393

DTIC
hepatic toxicity of, 321

DVB (cisplatin, vindesine, and bleomycin)
combination chemotherapy for esophageal carcinoma, 781

Dysmyelopoietic syndrome
effect of chemotherapy for, 601

E

Effusions, malignant
administration of BCG cell wall skeleton into: toxic and therapeutic effects, 383

Esophageal cancer *see* Cancer, esophageal

Estrogen receptors
influence of status on response to combination chemotherapy for recurrent breast cancer, 763

Ethinyl estradiol
medroxyprogesterone and, treatment in advanced breast cancer: a pilot study, 135
versus tamoxifen in the treatment of postmenopausal women with advanced breast cancer, 179

Etoposide *see* VP-16-213

F

Ftorafur
effect of thymidine on the toxicity and antitumor activity of, 1087
serum concentrations of 5-FU, ftorafur, and a major metabolite following chemotherapy with, 69
treatment of advanced adenocarcinoma of the lung with doxorubicin, cyclophosphamide, cisplatin and, (FACP), 197

5-FU
cardiotoxicity, 1123
chemotherapy for colorectal cancer with a combination of PALA and, 747
combination therapy with PALA and, phase I trial, 331
doxorubicin, vincristine and, versus cyclophosphamide in advanced squamous cell carcinoma of the cervix, phase II randomized study, 901
melphalan, vincristine and, in advanced colonic carcinoma: results of a pilot study, 869
serum concentrations following ftorafur chemotherapy, 69

treatment of small cell anaplastic carcinoma of the lung: a phase II trial, 123
Furosemide
diuresis induced by, versus mannitol diuresis in high-dose cisplatin therapy: comparative pharmacokinetics and toxicity, 73

G

Glutaminase-asparaginase
of *Achromobacter*, covalently attached to polyethylene glycol, immunosuppressive properties and circulating life in man, 1077

H

Hair pigmentation changes *see* Adverse effects, man
HAM (hexamethylmelamine, doxorubicin, and methotrexate)
chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, 959
versus CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine), chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, 959
Head and neck cancer *see* Cancer, head and neck
Hepatic toxicity *see* Adverse effects, man
Hexamethylmelamine
and *N*-demethylated metabolites, cerebrospinal fluid levels of, 350
chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP, 959
combination with doxorubicin and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy, 172
cyclophosphamide and, compared with doxorubicin and cyclophosphamide in combination chemotherapy for advanced ovarian cancer: a prospective randomized trial, 137
cyclophosphamide, doxorubicin, cisplatin and, as second-line chemotherapy for ovarian adenocarcinoma, 149
in mustard-resistant ovarian adenocarcinoma, 530
in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia, phase II study of, 1027
Hydrocortisone
vincristine, intrathecal methotrexate and intrathecal hydrocortisone, in adjuvant chemotherapy for medulloblastoma and ependymoma: a Southwest Oncology Group study, 681
Hydroxyurea
medroxyprogesterone, nafoxidine and, in treatment of renal carcinoma: a phase III randomized trial, 689
Hypercalcemia
dichloromethylene diphosphonate (iv) in cancer-associated, a phase I-II evaluation, 651
Hyperthermia
erythrocyte osmotic fragility in patients receiving, with and without chemotherapy, 1103
Hypothermia
combined with doxorubicin hypogastric artery infusion for transitional cell carcinoma of the bladder, 891

I

ICRF-159
combined with daunorubicin or doxorubicin, studies in mice treated with, 267
ICRF-187
by 48-hour continuous infusion, phase I trial of, 459
using a daily for 3 days schedule, phase I study, 249
Ifosfamide
weekly dose fractionated schedule in bronchogenic carcinoma, 693
Immunosuppression *see* Adverse effects, animals
IMPY
in a twice weekly schedule, phase I evaluation of, 439
INDI *see* Indicine-*N*-oxide
Indicine-*N*-oxide
a new antitumor agent, 53
in patients with advanced colorectal carcinoma, phase II trial of, 337

L

L1210 leukemia *see* Tumor systems, animals
Leukemia
acute myelocytic
efficacy of piperazinedione prior to bone marrow transplantation: studies in a rat model for human, 575
presenting with high wbc counts, factors affecting survival of patients with, 1007
acute nonlymphocytic
effective remission induction of refractory childhood, by VP-16-213 plus azacitidine, 995
acute
childhood lymphoblastic in relapse, comparison of the therapeutic response of patients with, to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial, 1015
3-deazauridine in adults with, phase I-II study, 521
dianhydrogalactitol for remission induction in children with, phase II clinical trial: a Southwest Oncology Group study, 121
lymphoblastic, late reinforcement of maintenance therapy in children with, 164
lymphocytic, intermittent continuous iv infusion of high-dose cyclophosphamide for remission induction in, 213
pyrazofurin and azacitidine in refractory adult, phase I study, 237

rubidazone in adults with previously treated, and blast cell phase chronic myelocytic leukemia: a Southwest Oncology Group study, 427
chlorozotocin in leukemia and other hematologic malignancies, phase II study, 1109
chronic
lymphocytic, hexamethylmelamine in refractory Hodgkin's disease, other lymphomas and, phase II study, 1027
granulocytic
chronic, intensive chemotherapy with daunorubicin, azacitidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of, 389
hairy cell
long-term chemotherapy-induced remission in a probable case of, 313
myelocytic
rubidazone in adults with blast cell phase chronic, and previously treated acute leukemia: a Southwest Oncology Group study, 427
relapsed
combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of, 377
Leucovorin
pharmacokinetics of rescue with, using a new methotrexate-independent biochemical assay for leucovorin and N^5-methyltetrahydrofolate, 545
Levodopa
and dopamine analogs: dihydroxy- and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo, 861
Lung cancer *see* Cancer, lung
Lymphoma *see* Cancer, lymphoma

M

Mannitol
diuresis induced by, versus furosemide diuresis in high-dose cisplatin therapy: comparative pharmacokinetics and toxicity, 73
Mechlorethamine
unanticipated side effects from treatment with high-dose, in patients with malignant melanoma, 327
Medroxyprogesterone
ethinyl estradiol and, treatment in advanced breast cancer: a pilot study, 135
hydroxyurea, nafoxidine and, in treatment of renal carcinoma: a phase III randomized trial, 689
Meeting reports
working conference on neuroblastoma treatment trials, 719
workshop on intraoperative radiation therapy, summary of, 911
Melphalan
high-dose, and autologous bone marrow transplantation, treatment of Ewing's sarcoma with, 241
uptake by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid, 157
vincristine, 5-FU and, in advanced colonic carcinoma: results of a pilot study, 869
Methotrexate
anaphylactic reaction to high doses in adjuvant treatment of osteogenic sarcoma, 725
and 5-methyltetrahydrohomofolate, disposition in rats, 101
biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide in murine L1210 leukemia, 107
chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP, 959
cisplatin, bleomycin and, (PBM) in treatment of advanced squamous cell carcinoma of the head and neck, 787
cyclophosphamide, doxorubicin, procarbazine and, (CAMP) for epidermoid and large cell anaplastic carcinoma of the lung, 317
high-dose, effects of vincristine and, on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma, 739
reversal of toxicity in mice by a calcium salt of citrovorum factor and related compounds, 1117
vincristine, intrathecal hydrocortisone, and intrathecal methotrexate in adjuvant chemotherapy for medulloblastoma and ependymoma: a Southwest Oncology Group study, 681
vindesine versus vincristine in combination with, against L1210 leukemia, increased schedule-dependent synergism of, 1049
Methyl-GAG
in advanced renal cancer, phase II trial, 525
in patients with refractory metastatic breast cancer, phase II evaluation, 465
plasma levels and urinary excretion following iv infusion in man, 253
N^5-Methyltetrahydrofolate
pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and, 545
5-Methyltetrahydrohomofolate
and methotrexate, disposition in rats, 101
Metoprine
in patients with advanced colorectal cancer, phase II evaluation, 127
β_2-Microglobulin
measurement of urinary, in the detection of cisplatin nephrotoxicity, 1083
Mitolactol
doxorubicin, mitomycin C and, treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 33
evaluation of an intermittent schedule of, in advanced non-small cell cancer, 1099
Mitomycin C
doxorubicin, mitolactol (dibromodulcitol) and, treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone, 33

four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group pilot study, 143
skin ulceration induced by, remote from infusion site, 529

N

Nafoxidine
medroxyprogesterone, hydroxyurea and, in treatment of renal carcinoma: a phase III randomized trial, 689
Neocarzinostatin
report of a phase II clinical trial, 699
Nitrosoureas
synergistic antileukemic activity of combinations of two, 591
Nocardia rubra
cell wall skeleton, phase I study with, 707

O

Ovarian cancer *see* Cancer, ovarian

P

PALA
combination therapy with 5-FU, phase I trial, 331
combination with 5-FU in chemotherapy for colorectal cancer, 747
in advanced large bowel carcinoma, phase II study, 335
in patients with advanced head and neck cancer, phase II evaluation, 827
Pancreatic cancer *see* Cancer, pancreatic
PBM (cisplatin, bleomycin, and methotrexate)
treatment of advanced squamous cell carcinoma of the head and neck with, 787
PCNU
administered by 5-day courses, phase I trial, 835
responses to azacitidine, aziridinylbenzoquinone, cisplatin and: chemotherapeutic trials with hamster mesothelioma 10-24, 1113
Pentamethylmelamine
clinical and pharmacologic study, phase I trial, 755
Pharmacokinetics
BCNU, differential pulse polarographic determination in patients with lung cancer, 555
comparison in high-dose cisplatin therapy, 73
evaluation of cisplatin in children with malignant solid tumors: a phase II study, 1021
hexamethylmelamine and pentamethylmelamine in mice, 669
high-dose therapy with cisplatin using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity, 73
kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis, 665
of bleomycin after im administration in man, 485
of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N^5-methyltetrahydrofolate, 545
of vincristine infusion, 1043
phase I and pharmacokinetic studies of DON, 1031
systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study, 477
Phase I studies
and pharmacokinetic studies of DON, 1031
bruceantin administered on a weekly schedule, 883
chlorozotocin trial, attempted amelioration of myelotoxicity by glucose administration, 647
clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule, 841
combination therapy with PALA and 5-FU, 331
combined radiotherapy and bleomycin for advanced head and neck cancers: results of a pilot study, 697
3-deazauridine in adults with acute leukemia, 521
dichloromethylene diphosphonate, iv, in cancer-associated hypercalcemia: a phase I-II evaluation, 651
dihydroxyanthracenedione trial, 831
high-dose melphalan and autologous bone marrow transplantation, treatment of Ewing's sarcoma with, 241
ICRF-187 trial by 48-hour continuous infusion, 459
ICRF-187 using a daily for 3 days schedule, 249
IMPY, evaluation of a twice weekly schedule, 439
methyl-GAG in treatment of patients with metastatic renal adenocarcinoma, 17
PCNU administered by 5-day courses, 835
pentamethylmelamine: a clinical and pharmacologic study, 755
pyrazofurin and 5-azacytidine in refractory adult acute leukemia, 237
study with cell wall skeleton of *Nocardia rubra*, 707
VP-16-213 (etoposide) administered as a continuous 5-day infusion, 887
Phase II studies
AMSA in lung cancer, 655
AMSA in patients with refractory small cell carcinoma of the lung, 133
anguidine in patients with sarcomas unresponsive to prior chemotherapy: a Southwest Oncology Group study, 881
broad phase II study of vindesine, 877
chlorozotocin evaluation in patients with advanced sarcomas, 513
chlorozotocin in leukemia and other hematologic malignancies, 1109
chlorozotocin in patients with malignant melanoma, 705
chlorozotocin in the treatment of advanced colorectal cancer, 13
chlorozotocin treatment of advanced soft tissue sarcomas: a phase II trial of EORTC Soft Tissue and Bone Sarcoma Group, 509
cisplatin in refractory childhood cancer: Children's Cancer Study Group report, 815
cisplatin in small cell carcinoma of the lung, 905
cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma, 897

clinical trial of VP-16-213 in ovarian cancer, 329
combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer, 517
3-deazauridine in adults with acute leukemia, 521
dianhydrogalactitol evaluation in lung cancer: a Southwest Oncology Group study, 115
dianhydrogalactitol for remission induction in children with acute leukemia: a Southwest Oncology Group study, 121
dichloromethylene disphosphonate, iv, in cancer-associated hypercalcemia: a phase I-II evaluation, 651
diglycoaldehyde in malignant melanomas and soft tissue sarcomas, 823
evaluation of AMSA in adult sarcomas, 341
evaluation of methyl-GAG in patients with refractory metastatic breast cancer, 465
5-FU in the treatment of small cell anaplastic carcinoma of the lung, 123
hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia, 1027
indicine *N*-oxide (INDI) in patients with advanced colorectal carcinoma, 337
iv 6-thioguanine in advanced colorectal carcinoma, 909
methyl-GAG in advanced renal cancer, 525
methyl-GAG in treatment of patients with metastatic renal adenocarcinoma, 17
metoprine evaluation in patients with advanced colorectal carcinoma, 127
neocarzinostatin: report of a phase II clinical trial, 699
new drugs in ovarian cancer and malignant melanoma: in vitro screening with the human tumor stem cell assay, 1
oral VP-16-213 in transitional cell carcinoma of the bladder, 703
PALA in advanced large bowel carcinoma, 335
PALA in patients with advanced head and neck cancer, 827
pharmacokinetic evaluation of cisplatin in children with malignant solid tumors, 1021
progestin therapy for advanced ovarian cancer: a phase II Eastern Cooperative Oncology Group trial, 895
randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix, 901
results of a protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST 2575, generation 1), 431
rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group study, 427
spirogermanium in advanced ovarian malignancy, 119
vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer, 711
vindesine in patients with metastatic breast cancer, 659
vindesine in patients with small cell lung carcinoma, 129
vindesine sulfate in patients with advanced sarcomas, 515
VP-16-213 evaluation in patients with advanced breast cancer: a Southwest Oncology Group study, 443

Phase III studies
comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial, 1015
randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine in treatment of renal carcinoma, 689
Piperazinedione
efficacy of, prior to bone marrow transplantation: studies in a rat model for human acute myelocytic leukemia, 575
Prednisone
adrenal response to serial cosyntropin stimulation after repeated high-dose administration in patients with lymphoma, 563
comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with L-asparaginase and: a phase III trial, 1015
treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin and, (VBAP): a Southwest Oncology Group study, 611
Procarbazine
chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP, 959
cyclophosphamide, doxorubicin, methotrexate and, (CAMP) for epidermoid and large cell anaplastic carcinoma of the lung, 317
Progestin
therapy for advanced ovarian cancer: a phase II Eastern Cooperative Oncology Group trial, 895
Pulmonary toxicity *see* Adverse effects, animals, man
Pyrazofurine
azacitidine and, in refractory adult acute leukemia, phase I study, 237

R

Radiation therapy
assessment of in vivo effectiveness of tumoricidal chemotherapy and, by serial analysis of tumor-associated urinary antigen titers in patients with sarcoma, 1037
Radioimmunoassay
determination of tissue concentrations of vinca alkaloids by, 469
Renal cancer *see* Cancer, renal
Rubidazone
in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group study, 427

S

Skin ulceration *see* Adverse effects, man
Spirogermanium
in advanced ovarian malignancy, phase II study of, 119

T

Talisomycin
pulmonary toxicity studies of bleomycin and, 291
Tamoxifen
effect in premenopausal Japanese women with advanced breast cancer, 728
in metastatic renal cell carcinoma and the influence of certain prognostic factors: a Southwest Oncology Group study, 447
induced regression of cerebral metastases in breast carcinoma, 793
treatment of malignant melanoma, 531
versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer, 179
Testicular cancer *see* Cancer, testicular
6-Thioguanine
in advanced colorectal carcinoma, phase II trial, 909
intensive chemotherapy with daunorubicin, 5-azacytidine, cytarabine and, for the blastic transformation of chronic granulocytic leukemia, 389
Thrombosis *see* Adverse effects, man
Thymidine 5′-*O*-pivaloate
evidence for prodrug action in the rat and rhesus monkey, 93
Thymidine
disposition of, administered as large doses to rats and mice, 495
effect of, on the toxicity and antitumor activity of ftorafur, 1087
"high-dose," in clinical oncology, 57
Toxicity *see* Adverse effects, animals, man
Triazinate
vinblastine-CCNU, dactinomycin and, in advanced renal cell cancer, 711
Trihydroxybenzylamines
dihydroxybenzylamines and, as novel quinol antitumor agents in experimental leukemia in vivo, 861
Tuftsin
antitumor activity on murine melanoma in vivo, 673
Tumor systems, animal
murine fibrosarcoma
in vivo cell cycle phase-preferential killing of cells by cisplatin, 845
C3H mammary carcinoma
selective enhancement by cisplatin of radiation response in, 501
EL4 leukemia
improved antitumor activity of basic amino acid and dipeptide derivatives of daunorubicin in mice, 277
hamster mesothelioma 10-24
chemotherapeutic trials with: responses to azacitidine, aziridinylbenzoquinone, cisplatin, and PCNU, 1113
L1210 ascites
rescue of thymidine cytotoxicity in, by elevated endogenous levels of deoxycytidine, 853
L1210 leukemia
biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine, 107
increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against, 1049
levodopa and dopamine analogs: dihydroxy- and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo, 861
Madison 109 lung carcinoma
evaluation as a model for screening antitumor drugs, 299
malignant and normal mouse tissue, experimental studies on the radiation-modifying effect of bleomycin in, 583
murine melanoma
in vivo antitumor activity of tuftsin on, 673
murine Sarcoma 180
action of demecolcine (Colcemid) in, 283
P388 leukemia
levodopa and dopamine analogs: dihydroxy- and trihydroxybenzylamines as novel quinol antitumor agents in experimental leukemia in vivo, 861
rat mammary tumors
enhanced cytostatic effectiveness of analine mustard against 7,12,-dimethylbenz(*a*)anthracene-induced, during regression in response to ovariectomy, 567
rat model for human acute myelocytic leukemia
efficacy of piperazinedione prior to bone marrow transplantation, 575
studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin, 267
synergistic antileukemic activity of combinations of two nitrosoureas, 591

V

VBAP (vincristine, BCNU, doxorubicin, and prednisone)
treatment of recurrent lymphomas with: a Southwest Oncology Group study, 611
V-CAP (VP-16-213, cyclophosphamide, doxorubicin, and cisplatin)
evaluation in advanced large cell lung cancer, 715
VCR *see* Vincristine
Vinblastine
combination with bleomycin in metastatic renal cell carcinoma, 349
Vinblastine-CCNU
triazinate, dactinomycin and, in advanced renal cell cancer, 711
Vinca alkaloids
determination of tissue concentrations by radioimmunoassay, 469
Vincristine
combination with CCNU and bleomycin, re-evaluation in the treatment of malignant disseminated melanoma, 505
doxorubicin, 5-FU and, versus cyclophosphamide in advanced squamous cell carcinoma of the cervix, phase II randomized study, 901
effects of, and high-dose methotrexate on ovarian and

testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma, 739
intrathecal methotrexate, intrathecal hydrocortisone and, in adjuvant chemotherapy for medulloblastoma and ependymoma: a Southwest Oncology Group study, 681
melphalan, 5-FU and, in advanced colonic carcinoma: results of a pilot study, 869
pharmacokinetics of infusion, 1043
treatment of recurrent lymphomas with BCNU, doxorubicin, prednisone and, (VBAP): a Southwest Oncology Group study, 611
versus vindesine in combination with methotrexate against L1210 leukemia, increased schedule-dependent synergism of, 1049
versus vindesine in combination with prednisone and L-asparaginase, comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to: a phase III trial, 1015

Vindesine
broad phase II study of, 877
combination with cisplatin and bleomycin (DVB), chemotherapy for esophageal carcinoma, 781
in patients with metastatic breast cancer, phase II study, 659
in patients with small cell lung carcinoma, phase II trial, 129
in treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion, 775
in treatment of small cell anaplastic bronchogenic carcinoma, 245
initial clinical studies of, 873
sulfate, in patients with advanced sarcomas, phase II evaluation, 515
versus vincristine in combination with methotrexate against L1210 leukemia, increased schedule-dependent synergism of, 1049
versus vincristine in combination with prednisone and L-asparaginase, comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to: a phase III trial, 1015

VND *see* Vindesine

VP-16-213
administered as a continuous 5-day infusion, phase I study of, 887
combination with high-dose cyclophosphamide and BCNU followed by autologous marrow rescue in the treatment of relapsed leukemia, 377
cyclophosphamide and, with or without cisplatin in squamous cell and small cell lung cancers, 453
evaluation of cyclophosphamide, doxorubicin, cisplatin and, (V-CAP) in advanced large cell lung cancer, 715
in ovarian cancer, phase II clinical trial, 329
in patients with advanced breast cancer, phase II evaluation: a Southwest Oncology Group study, 443
oral, in transitional cell carcinoma of the bladder: a phase II study, 703
plus azacitidine, effective remission induction of refractory childhood acute nonlymphocytic leukemia by, 995
treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: an interim report, 987

Z

Zinostatin
pulmonary toxicity related to, 165

Index of Clinical Trials Letters
by *Drug* and *Tumor*

Drug

AMSA
in patients with metastatic malignant melanoma, phase II study of, 170
PALA and, for patients with disseminated malignant melanoma, phase II evaluation, 169
Anguidine
combination of 5-FU and, therapy for advanced colorectal cancer with: a Southwest Oncology Group study, 359
BCNU
sequential combination chemotherapy for disseminated melanoma: a Southwest Oncology Group study, 732
Bleomycin
sequential combination chemotherapy for disseminated melanoma: a Southwest Oncology Group study, 732
vincristine, methotrexate and, (BOM) in squamous cell carcinoma of the lung: a phase II study, 171
Chlorambucil
double alkylator (thiotepa plus chlorambucil) for previously treated advanced ovarian cancer, 731
Chlorozotocin
in advanced breast cancer, a phase II study of, 537
in non-small cell carcinoma of the lung, phase II study of, 734
Cycloleucine
in the treatment of patients with disseminated sarcomas, phase II evaluation of, 358
Cyclophosphamide
hexamethylmelamine and, in non-oat cell bronchogenic carcinoma, phase II study of, 731
hexamethylmelamine, doxorubicin and, in advanced ovarian cancer resistant to previous chemotherapy, 172
Dianhydrogalactitol
dianhydrogalactitol in the treatment of children with primary brain tumors, 923
Doxorubicin
hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy, 172
DTIC
sequential combination chemotherapy for disseminated melanoma: a Southwest Oncology Group study, 732
5-FU
combination with anguidine, therapy for advanced colorectal cancer: a Southwest Oncology Group study, 359
melphalan plus, in advanced colorectal carcinoma, phase II study, 735
methotrexate, mitomycin and, in advanced colorectal adenocarcinoma: a phase II study, 924
Hexamethylmelamine
cyclophosphamide, hexamethylmelamine and, in non-oat cell bronchogenic carcinoma, phase II study of, 731
doxorubicin, cyclophosphamide and, in advanced ovarian cancer resistant to previous chemotherapy, 172
Ifosfamide
treatment of pancreatic cancer, 357

Maytansine
in advanced breast cancer, phase II study of, 536
Melphalan
5-FU plus, in advanced colorectal carcinoma, phase II trial, 735
Methotrexate
bleomycin, vincristine and, (BOM) in squamous cell carcinoma of the lung: a phase II study, 171
5-FU, mitomycin and, in advanced colorectal adenocarcinoma: a phase II study, 924
high-dose in patients with unresectable metastatic osteosarcoma, phase II study of, 538
mitomycin and, combination therapy for advanced colorectal carcinoma: phase II trial, 535
Mitomycin
combination with methotrexate for advanced colorectal carcinoma: phase II trial, 535
5-FU, methotrexate and, in advanced colorectal adenocarcinoma: a phase II study, 924
Mitotane
a preliminary report of mitotane therapy for advanced renal and prostate cancer, 539
PALA
AMSA and, for patients with disseminated malignant melanoma, phase II evaluation, 169
in patients with metastatic lung cancer, phase II evaluation, 356
PCNU
in colorectal carcinoma, phase II study, 1129
Pyrazofurin
razoxane and, in alkylating agent-resistant cases of epithelial ovarian carcinoma, concomitant phase II studies of, 1127
Razoxane
pyrazofurin and, in alkylating agent-resistant cases of epithelial ovarian carcinoma, concomitant phase II studies of, 1127
Thiotepa
double alkylator (thiotepa plus chlorambucil) for previously treated advanced ovarian cancer, 731
Vincristine
bleomycin, methotrexate and, (BOM) in squamous cell carcinoma of the lung: a phase II study, 171
Vindesine
in metastatic malignant melanoma, phase II study of, 355
Zinostatin
in children with late-stage acute lymphocytic leukemia, phase II trial of: a Pediatric Oncology Group study, 173

Tumor

Brain
primary, dianhydrogalactitol in the treatment of children with, 923
Breast
advanced, chlorozotocin in, phase II study, 537
advanced, maytansine in, phase II study, 536
Bronchogenic
non-oat cell, cyclophosphamide and hexamethylmelamine in, phase II study, 731
Colorectal
advanced adenocarcinoma, 5-FU, methotrexate, and mitomycin in: a phase II study, 924
advanced, 5-FU plus melphalan in, phase II trial, 735

advanced, mitomycin and methotrexate combination therapy for: phase II trial, 535
advanced, therapy for, with a combination of 5-FU and anguidine: a Southwest Oncology Group study, 359
carcinoma, PCNU in, phase II study, 1129
Leukemia
late-stage acute lymphocytic, phase II trial of zinostatin in children with: a Pediatric Oncology Group study, 173
Lung
bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study, 171
metastatic, PALA in patients with, phase II evaluation, 356
non-small cell carcinoma, chlorozotocin in, phase II study, 734
Melanoma
disseminated malignant, PALA and AMSA for patients with, phase II evaluation, 169
disseminated, sequential combination chemotherapy for: a Southwest Oncology Group study, 732
metastatic malignant, AMSA in patients with, phase II study, 170
metastatic malignant, vindesine in, phase II study, 355
Osteosarcoma
unresectable metastatic, high-dose methotrexate in patients with, phase II study, 538
Ovarian
advanced and resistant to previous chemotherapy, hexamethylmelamine, doxorubicin, and cyclophosphamide in, 172
double alkylator (thiotepa plus chlorambucil) for previously treated advanced ovarian cancer, 731
epithelial carcinoma, pyrazofurin and razoxane in alkylating agent-resistant cases of, 1127
Pancreatic
ifosfamide treatment of, 357
Prostatic
advanced renal and, preliminary report of mitotane therapy for, 539
Sarcoma
disseminated, cycloleucine in the treatment of, phase II evaluation, 358